Valuation
- Market cap
- 2,122,163,000
- Revenue TTM
- $283,060,000
- Net income TTM
- $287,200,000
- PE ratio
- 15.88
- Forward PE
- 17.99
- Profit margin
- 101.46%
- Debt to equity
- 0.00
Trading
- Volume
- 813,400
- Avg volume
- 1,001,838
- Day's range
- $15.74 – $16.06
- Shares out
- 133,051,000
- Stochastic %K
- 8%
- Beta
- 1.60
- Analysts
- Strong Sell
- Price target
- $17.86
Company profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducin...
Show more
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 250 744 2487
- Website
- https://www.auriniapharma.com
- Address
- #140, 14315 – 118 Avenue, Edmonton, Canada
Latest news
No headlines yet.
